| | Variable | Number, mean +/− SD | % |
| | Gender | M | 24 | 62% | | F | 15 | 38% |
| | Age (mean +/− SD) | 59,1 +/− 7,6 | — |
| | Age group | 15–25 | 2 | 5,1% | | 25–35 | 2 | 5,1% | | 35–45 | 2 | 5,1% | | 45–55 | 4 | 10,2% | | 55–65 | 14 | 35,9% | | 65–75 | 11 | 28,2% | | 75–85 | 4 | 10,2% |
| | Underlying illness | Essential hypertension | 13 | 34,2% | | Diabetes mellitus | 12 | 30,8% | | Immunosuppression | 3 | 8,1% | | Chronic renal disease | 2 | 5,4% | | Ischemic heart disease | 4 | 10,4% | | Others | 12 | 31,6% |
| | Severity | Sepsis | 23 | 50% | | Severe sepsis | 8 | 17,4% | | Septic shock | 15 | 32,6% |
| | Scores of gravity | GLASGOW II | 10,14 +/− 3,76 | — | | APACHE II | 18,95 +/− 3,76 | — | | Predicted mortality | 35,07 +/− 22,2 | — |
| | Length of stay | 41 +/− 6,4 | — |
| | Antecedents | Recent antibiotic use | 13 | 33,3% | | Recent hospitalization | 23 | 59% | | Recent surgery | 14 | 34,5% | | Recent corticosteroid therapy | 24 | 61,5% |
| | Outcome | Clinical failure | 17 | 44% | | Clinical success | 22 | 56,5% |
| | Bacteraemia acquisition time | 16,2 +/− 20,27 | — |
|
|
